The intricate interplay between neuropharmacology and neurodegenerative disorders has become increasingly apparent as research dives into the complexities of the nervous system. Approaching Alzheimer's 2024, the imminent scientific session on this topic holds significant promise for unveiling innovative therapeutic strategies and gaining a deeper understanding of the fundamental mechanisms contributing to neurodegeneration.
At the forefront of this discourse is the investigation of pharmacological agents designed to target specific molecular pathways implicated in Alzheimer's disease. The development of drugs that modulate neurotransmitter systems, regulate protein aggregation, and enhance neuroprotective mechanisms offers the potential to arrest or even reverse the progression of this debilitating disorder.
The scientific session on neuropharmacology and neurodegenerative diseases at Alzheimer's 2024 is poised to be a pivotal platform for the exchange of cutting-edge findings, the cultivation of collaborations, and the acceleration of efforts toward effective treatments for Alzheimer's disease and other neurodegenerative conditions.
All accepted abstracts will be published in respective Allied Academies Journals.
Abstracts will be provided with Digital Object Identifier by
